Questcor Pharmaceuticals — Q4 2011 Earnings Presentation
11 slides from Questcor Pharmaceuticals's earnings presentation, Feb 27, 2012
Slide 1: Fourth Quarter 2011 Conference Call
Fourth Quarter 2011 Conference Call NASDAQ: QCOR Exhibit 99.3 Fourth Quarter 2011 Conference Call NASDAQ: QCOR
Slide 2: Conference Call Logistics
2 • Today’s webcast, accompanying slide presentation and archived replay is available online at • Telephone replay is available by dialing: – U.S.: 800-406-7325 – International: 303-590-3030 – Replay Passcode: 4480054 Conference Call Logistics http://ir.questcor.com/events.cfm • Today’s webcast, acc
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 4: Strong Fourth Quarter Results
4 • 945 paid MS scripts – Up 167% YOY • 146 paid NS scripts • 120 paid IS scripts • Record financial performance – 3,360 vials – $75.5M in net sales – $0.48 EPS (diluted) Strong Fourth Quarter Results • 945 paid MS scripts – Up 167% YOY • 146 paid NS scripts • 120 paid IS scripts • Record financial
Slide 5: MS Scripts - Record of Consistent Growth
5 MS Scripts-Record of Consistent Growth Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descripti
Slide 6: Monthly MS Scripts History
6 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the c
Slide 7: NS Scripts - Strong Q4 Growth
7 Paid Rxs NS Scripts-Strong Q4 Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of
Slide 8: Q4-2011 Financial Results
8 Q4 – 2011 Q4 – 2010 Q4-2011 Financial Results • Fourth quarter vials shipped: 3,360 • Fourth quarter cash flow from operations: $31.4M • Channel inventory estimated to be within historic range • Medicaid reserves continue to appear adequate • No shares repurchased Record Net Sales (up 158%) and So
Slide 9: 2011 Financial Results
9 2011 2010 2011 Financial Results • Total vials shipped: 10,710 • Cash flow from operations: $85.6M • Channel inventory estimated to be within historic range • Medicaid reserves continue to appear adequate • 884,300 shares repurchased Record Net Sales (up 90%) and Solid Earnings (EPS up 124%) Net S
Slide 10: Questcor is Cash Flow Positive
10 02/15/12 Questcor is Cash Flow Positive Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments $226M* Accounts Receivable $44M Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurcha
Slide 11: Investment Highlights
11 Investment Highlights Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need in l
Questcor Pharmaceuticals — Q4 2011 Earnings Presentation on 6ix